

DTIC FILE COPY

①

AD \_\_\_\_\_

AD-A224 812

CONTRACT NO: DAMD17-83-C-3031

TITLE: DEVELOPMENT OF SEROLOGIC ASSAYS FOR THE DIAGNOSIS OF  
NEW WORLD LEISHMANIASIS

PRINCIPAL INVESTIGATOR: Ronald L. Anthony, Ph.D.

CONTRACTING ORGANIZATION: University of Maryland  
School of Medicine  
Baltimore, Maryland 21201

REPORT DATE: February 25, 1986

TYPE OF REPORT: Final Report

PREPARED FOR: U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND  
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The findings in this report are not to be construed as an  
official Department of the Army position unless so designated by  
other authorized documents.

DTIC  
SELECTED  
JUL 31 1990  
S  
D &

20 07 80 130

| REPORT DOCUMENTATION PAGE  |                       | READ INSTRUCTIONS<br>BEFORE COMPLETING FORM                        |
|--|-----------------------|--|
| 1. REPORT NUMBER<br>04   | 2. GOVT ACCESSION NO. | 3. RECIPIENT'S CATALOG NUMBER                                      |
| 4. TITLE (and Subtitle)<br>Development of Serologic Assays for the<br>Diagnosis of New World Leishmaniasis   |                       | 5. TYPE OF REPORT & PERIOD COVERED<br>Final<br>12/1/82 to 11/30/86 |
|  |                       | 6. PERFORMING ORG. REPORT NUMBER                                   |
| 7. AUTHOR(s)<br>Ronald L. Anthony, Ph.D.<br>Associate Professor  |                       | 8. CONTRACT OR GRANT NUMBER(s)<br><br>DAMD-17-83C-3031             |
| 9. PERFORMING ORGANIZATION NAME AND ADDRESS<br>University of Maryland School of Medicine<br>Baltimore, Maryland 21201  |                       | 10. PROGRAM ELEMENT, PROJECT, TASK<br>AREA & WORK UNIT NUMBERS     |
| 11. CONTROLLING OFFICE NAME AND ADDRESS  |                       | 12. REPORT DATE<br>February 25, 1986                               |
|  |                       | 13. NUMBER OF PAGES<br>8   |
| 14. MONITORING AGENCY NAME & ADDRESS (If different from Controlling Office)  |                       | 15. SECURITY CLASS. (of this report)                               |
|  |                       | 15a. DECLASSIFICATION/DOWNGRADING<br>SCHEDULE                      |
| 16. DISTRIBUTION STATEMENT (of this Report)<br><br>Approved for public release:distribution unlimited  |                       |  |
| 17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)   |                       |  |
| 18. SUPPLEMENTARY NOTES  |                       |  |
| 19. KEY WORDS (Continue on reverse side if necessary and identify by block number)<br><br>Leishmania; monoclonal antibodies; serodiagnosis; antigens;<br><br>ELISA; immunopathology. <i>ITS</i>  |                       |  |
| 20. ABSTRACT (Continue on reverse side if necessary and identify by block number)<br><br>Murine monoclonal antibodies have been used to recover the<br>genus-specific antigens of the New World Leishmania. These<br>antigens have been used for the development of species-specific<br>serodiagnostic assays and to study the immunopathogenesis of the<br>disease. Seven manuscripts and 10 abstracts have resulted from<br>these efforts. |                       |  |

## FOREWORD

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

|                    |                                     |
|--------------------|-------------------------------------|
| Availability Codes |                                     |
| NIS CRAGI          | <input checked="" type="checkbox"/> |
| DIC TAB            | <input type="checkbox"/>            |
| Unannounced        | <input type="checkbox"/>            |
| Justification      |                                     |
| By _____           |                                     |
| Distribution/      |                                     |
| Availability Codes |                                     |
| Dist               | Availability for Special            |
| A-1                |                                     |



## Narrative Summary:

### 1. Cultivation and maintenance of parasites:

The laboratory has become proficient in the maintenance and cultivation of both promastigotes and amastigotes of the leishmania species as well as epimastigotes of the trypanosomes. An inventory of parasite isolates which are now held in our cryobank can be found in our Annual Report No. 2 (1983-1984).

### 2. Monoclonal Antibody Production:

The laboratory has produced and characterized numerous panels of murine monoclonal antibodies to the surface and subcellular antigens of the major species and subspecies of New World Leishmania, *Leishmania cruzi* and *Leishmanosoma panzelli*. Immunogens have included extracts of whole cultured forms (promastigotes or epimastigotes), purified pellicular membranes, insect forms and amastigotes.

### 3. Use of monoclonal antibodies for the speciation of isolates:

The primary objective of our contract was to develop monoclonal antibodies for the speciation of New World Leishmania isolates. Although we were not successful in differentiation of some of the sub-species we are now confident in the genus-specificity of some antibodies and most importantly, our ability to differentiate members of the mexicana versus the braziliensis complex. However, the differences in surface antigen expression are often quantitative and not, as reported by others, commonly qualitative. The antigenic profiles of isolates from mucocutaneous disease are also very different from members of the same species from cutaneous disease. At least one monoclonal antibody is specific for an epitope which, thus far, is peculiar to a subpopulation of promastigotes of an Leishmania braziliensis panamensis isolate. Many of these monoclonals are now in use at WRAIR for the speciation of trypanosomatids recovered from sandflies collected in The Republic of Panama. Other monoclonals are being used at WRAIR for the speciation of leishmania recovered from human lesions.

### 4. Recovery of species- and strain-specific antigens:

The second major goal of the contract was to use the monoclonal antibodies as ligands, in immunoaffinity chromatography, for the recovery of strain-specific and species-specific antigens. A complete list of the antigens recovered and assessed is presented in the Annual Report No. 2 (1983-1984). The leishmania display four dominant genus-specific antigen on their surface membrane with molecular sizes of 72, 55, 42 and 15 kd respectively. The low molecular weight protein is also excreted into the medium which supports growth of the promastigotes. The 72 and 55 kd moieties have no external exposure, as determined by flow cytometry, and thus probably play little role, if any, in the immune response. Minor membrane antigens consisted of 4 additional polypeptides with kd values of 63, 58, 56 and 25. The three larger molecules share a common antigenic epitope. All of the antigens have been characterized and quantitated on the surface

membrane of all Leishmania isolates, by using techniques of immunoblotting and flow microfluorometry. Several have also been visualized by immunoelectronmicroscopy.

5. Development of enzyme linked immunosorbent assays to demonstrate serum antibodies against strain-specific and species-specific antigens of Leishmania:

Although we were not successful in developing an ELISA for detecting species-specific antibody responses (the third objective of the contract), we have recovered and purified a genus-specific antigen which is highly reactive with sera from human leishmaniasis but not reactive with sera from individuals with Chagas' disease. This antigen has now been used in several serosurveys in The Republic of Panama.

6. Use of monoclonal antibodies to detect parasites in infected tissues:

Another objective was to ascertain whether monoclonal antibodies could be used to enhance assays designed to detect intracellular amastigotes in biopsy specimens. Using a Balb/c mouse model, we were able to confirm that several of our monoclonal antibodies did facilitate identification of amastigotes in infected tissues. These monoclonal antibodies are now being used at WRAIR for the identification of amastigotes in human tissues.

7. Use of monoclonal antibodies to identify parasite antigens which may contribute to the pathology of the disease.

Throughout the course of these studies, we also discovered that several monoclonal antibodies can act as opsonins and actually enhance parasite binding and uptake by mouse peritoneal macrophages. The antigens recognized by these monoclonals have been characterized and purified. Conversely, several other monoclonals inhibit the binding and uptake of the parasites by the macrophages. We suspect that these antibodies are recognizing the parasite receptor which is required for attachment.

One monoclonal antibody recognized an parasite antigen which was expressed on the surface membrane of the parasitized macrophage. Flow cytometric analyses of the kinetics of expression of this antigen suggested that it has an intracellular origin and is processed within the phagolysosome. Results have also been confirmed by immunoelectronmicroscopy. This antigen has been purified and we now have evidence that it stimulates lymphocyte transformation *in vitro*. Its capacity to induce lymphokines involved in the activation of macrophages is currently under investigation.

Many other monoclonal antibodies recognized epitopes which have apparently been highly conserved throughout phylogeny and thus are expressed in vertebrate cells. These antibodies are reactive with an array of cytoskeletal elements, nuclear components and cytoplasmic organelles. The role which these cross-reactive antigens play in the immunopathogenesis of disease remains unclear.

Papers:

1. Anthony, R. L., K. M. Williams, J. B. Sacci and D. C. Rubin. 1985. Subcellular and taxonomic specificity of monoclonal antibodies to New World *Leishmania*. Am. J. Trop. Med. Hyg., 24: 1085-1094.
2. Williams, K. M., J. B. Sacci, and R. L. Anthony. 1986. Characterization and quantitation on membrane antigens of New World *Leishmania* species using monoclonal antibodies in western blot and flow microfluorometric assays. J. Protozool. (in press).
3. Williams, K. M., J. B. Sacci, and R. L. Anthony. 1986. Flow cytometric analysis of the effects exerted by monoclonal antibodies on binding and uptake of *Leishmania mexicana mexicana* promastigotes by murine peritoneal macrophages. Infect. Immun. (in press).
4. Williams, K. M., J. B. Sacci, and R. L. Anthony. 1986. Identification and recovery of *Leishmania* antigen displayed on the surface membrane of mouse peritoneal macrophages infected *in vitro*. J. Immunol. (in press).
5. Anthony, R. L., K. M. Williams and J. B. Sacci. 1986. Identification, recovery and immunogenicity of an antigen common to *Trypanosoma cruzi* and the vertebrate cell matrix. Infect. Immun. (submitted for publication).
6. Williams, K. M., J. B. Sacci, and R. L. Anthony. 1986. Rapid identification of *Leishmania* amastigotes using strain- and species-specific monoclonal antibodies. Am. J. Trop. Med. (submitted for publication).
7. Sacci, J. B., H. A. Christensen, A. Vasquez, and R. L. Anthony. 1986. Serodiagnosis of New World *Leishmania* by using a genus-specific antigen in enzyme linked immunosorbent assays. (in preparation).

Abstracts:

Anthony, R.L., and Constantine, N.T.: Identification and characterization of surface and subcellular antigens of *Trypanosoma cruzi* by means of monoclonal antibodies. Fed. Proc. 41: 585, 1982.

Anthony, R.L., Phelps, P.C., and Williams, K.M.: Serologic cross-reactivity between flagellar antigens on the Trypanosomatidae and cytoskeletal components of mammalian cells. Am. Soc. Trop. Med. Hyg., Cleveland, Ohio, November 11, 1982.

Constantine, N.T., Williams, K.M., and Anthony, R.L.: Visualization of leishmania in parasitized macrophages using monoclonal antibodies of four specificities. Am. Soc. Trop. Med. Hyg., Cleveland, Ohio, November 9, 1982.

Williams, K.M., Constantine, N.T., and Anthony, R.L.: Differentiation of New World *Leishmania* species by means of their reactivity with monoclonal antibodies in immunofluorescent assays. Fed. Proc. 42: 854, 1983.

Anthony, R.L., Phelps, P.C., and Williams, K.M.: Monoclonal antibodies to rat brain tubulin: Reactivity with cultured mammalian cells. Fed. Proc. 42: 1301, 1983.

Sacci, J.B., Williams, K.M., and Anthony, R.L.: Specificity of monoclonal antibodies to New World *Leishmania*: Assessment by enzyme linked immunosorbent assays. Am. Soc. Trop. Med. Hyg., Baltimore, MD. 1984.

Williams, K.M., Sacci, J.B., and Anthony, R.L.: Monoclonal antibodies recognizing stage-specific antigens of *Leishmania mexicana mexicana* and components of infected and uninfected peritoneal macrophages. Am. Soc. Trop. Med. Hyg., Baltimore, MD. 1984.

Anthony, R.L., Williams, K.M., and Sacci, J.B.: Specificity of monoclonal antibodies to parasitic trypanosomatids. Fourth European Congress of Parasitology, Izmir, Turkey, 1984.

Anthony, R.L., Sacci, J.B., and Williams, K.M.: Trypomastigotes of *Trypanosoma Cruzi* possess a 58 KD flagellar antigen which elicits antibodies to cytoskeletal polypeptides in human disease. Am. Soc. Trop. Med. Hyg., Miami, FL. 1985.

Sacci, J.B., Williams, K.M., and Anthony, R.L.: Promastigotes or *Leishmania braziliensis panamensis* have a genus - specific surface antigen which can be purified and used for the sero-diagnosis of human disease. Am. Soc. Trop. Med. Hyg., Miami, FL. 1985.

#### **SPECIAL LECTURES, INVITED SEMINARS**

Tropical Medicine Association of Washington, D.C. Guest speaker. NIAID, Bethesda, Maryland, February 25, 1982.

Tropical Medicine Course. Invited speaker. Walter Reed Army Institute of Research, Washington, D.C., July 23, 1982.

Thomas W. Holbrook Memorial Lectureship, Medical University of South Carolina, Charleston, SC, April 16, 1984.

Invited Lecture. Monoclonal antibodies and the antigenic dissection of New World *Leishmania*. Walter Reed Army Institute of Research. Washington, D.C. November 13, 1985.

Personnel:

-----  
Ronald L. Anthony, Ph.D. (Principal Investigator)  
Associate Professor of Pathology  
University of Maryland School of Medicine  
and  
Director of Clinical Immunology and Microbiology  
University of Maryland Medical System  
-----

Kristina M. Williams, Ph.D.

Graduate Student (1982-1984)  
Department of Pathology  
University of Maryland School of Medicine

Degree awarded September 1984.

Dissertation title:

"Structural and Functional Characteristics of Leishmania Membrane  
Antigens as Analyzed by Monoclonal Antibodies"

-----

John. B. Sacci

Graduate Student (1983-1986)  
Department of Pathology  
University of Maryland School of Medicine

Degree anticipated during fall of 1986.

Dissertation title:

"Immunogenic and Immunopathologic Properties of Leishmanial Antigens  
Identified by Murine Monoclonal Antibodies"

-----



DISTRIBUTION LIST:

Commander  
US Army Medical Research and Development Command  
ATTN: SGRD-RMS  
Fort Detrick  
Frederick, Maryland 21701  
(2 copies)

Office of Research Management  
SGRD-UWZ-C  
Walter Reed Army Institute of Research  
Washington D.C. 20307  
(1 copy)

James Lovelace  
Walter Reed Army Institute of Research  
WRAIR Building 40  
Washington D.C. 20012  
(1 copy)